Bottom line, this has further retracement in the charts. I would hold out for $18 range before opening a position.
Biotech is showing signs of weakness.
Of course they can. I'd still like to know, how many units did they sell? If it was that good, wouldn't they include it in the press release?
The PR says 'commercial sales', but neglects to tell us if they sold 2 units or 2000 units. Smells like a pump PR, usually ahead of a dilution filing.
Seriously, let the lawsuits follow. We should have known something stunk when the CFO resigned. No credibility with the company IMO.
Free money. I guess everyone forgot this is the only company with a CURE for ALS in active trials at 3 major research hospitals. Nevermind NSI-189 which is showing promising results in Alzheimer's patients...
That selling ahead of the earnings release was a clue. I've seen this with Biotech's before. Maybe it's the pancreatic trial, or side effects with the Ebola vaccine. I'm going to wait on the sidelines and see how this shakes out. I think we could see mid-20's or lower.
What aren't we being told?
This will continue to selloff into the day.
Probably best to wait.
I believe that was a relatively high grade fever no? Sure some muscle aches and headache might be tolerable. While it might be an attenuated virus, it's still live, and there is a very real risk of transmission to livestock. It would seem that risk only goes up with mass vaccination. It simply doesn't seem like the NLNK vaccine is the winner here, GSK has the safer, more widely accepted vaccine IMO. As for Rabies, can you disprove that VSV is in the Rhabdoviridae family of viruses? I certainly wouldn't sign up to get a vaccine like this. Name one other approved vaccine with VSV + protein.
NLNK's vaccine is based on Vesicular stomatitis virus with an added ebola gene. VSV belongs to the same families as Rabies. Ya, look it up: "Vesicular stomatitis Indiana virus (VSIV) (often still referred to as VSV) is a virus in the family Rhabdoviridae; the well-known rabies virus belongs to the same family."
Seems way to risky, and the CEO acknowledged it could pose a risk to live stock. Given the choice between a traditional vaccine from GSK or the one from NLNK, I'm pretty sure I know which one most people would choose. Can anyone clarify why this isn't a concern, or name one other approved vaccine that uses VSV?
The CEO, CFO, CQO...
5:56 pm NEWLINK GENETICS CORP NLNK LINK GORDON H JR
(Chief Financial Officer) 2,500 $40.39 $100,975 14,413
4:42 pm NEWLINK GENETICS CORP NLNK Ramsey William J.
(Quality Assurance Officer) 10,000 $40 $400,000 34,260
4:42 pm NEWLINK GENETICS CORP NLNK Link Charles J. Jr.
(Chairman of the Board and CEO
Director) 25,000 $40.26 $1,006,500 607,818
4:50 pm NEWLINK GENETICS CORP NLNK Ramsey William J.
(Quality Assurance Officer) 5,000 $30 $150,000 34,260
4:51 pm NEWLINK GENETICS CORP NLNK Link Charles J. Jr.
(Chairman of the Board and CEO
Director) 20,000 $22.71 $454,300 632,818
4:21 pm NEWLINK GENETICS CORP NLNK Ramsey William J.
(Quality Assurance Officer) 2,500 $23.25 $58,115 34,260
See the article in the Canadian Press this morning. If NewLink looses it's rights to this vaccine it's all over.
Wow, this is damaging. Go read the article published by the Canadian Press Today. NLNK is headed into a free fall. Wait for the BEAR RAID today.
"Canada urged to transfer Ebola vaccine licence to bigger company"
All 4 have come up recently, and make a compelling case to short NLNK back down into the low 20's. The only thing this stock has going for it is the the recent $150m deal with Roche. Comments?